CCND1 and lung carcinoma: Its mechanism of action includes modulating USP5 to enhance the ubiquitination of Cyclin D1 (CCND1), leading to a reduction in its expression levels and exhibiting a synergistic effect with paclitaxel in lung cancer treatment [59].